Jean-Noël Talbot

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11400828/publications.pdf

Version: 2024-02-01

331538 223716 2,229 58 21 46 citations h-index g-index papers 66 66 66 2219 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT, illustrative cases and pitfalls. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	0.4	3
2	An essential practice summary of the new EANM guidelines for parathyroid imaging. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 66, .	0.4	5
3	Patient external dose rate after 177Lu-DOTATATE therapy: factors affecting its decrease and predictive value. International Journal of Medical Sciences, 2021, 18, 2725-2735.	1.1	4
4	The EANM practice guidelines for parathyroid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2801-2822.	3.3	116
5	Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2935-2950.	3.3	14
6	68Ga-DOTATOC PET/CT in detecting neuroendocrine tumours responsible for initial or recurrent paraneoplastic Cushing's syndrome. Endocrine, 2020, 67, 708-717.	1.1	10
7	¹⁸ Fâ€fluorocholine PET/CT in MEN1ÂPatients with Primary Hyperparathyroidism. World Journal of Surgery, 2020, 44, 3761-3769.	0.8	25
8	A comparative study of peptide-based imaging agents [68Ga]Ga-PSMA-11, [68Ga]Ga-AMBA, [68Ga]Ga-NODAGA-RGD and [68Ga]Ga-DOTA-NT-20.3 in preclinical prostate tumour models. Nuclear Medicine and Biology, 2020, 84-85, 88-95.	0.3	13
9	Comparison of 18F-sodium fluoride PET/CT, 18F-fluorocholine PET/CT and diffusion-weighted MRI for the detection of bone metastases in recurrent prostate cancer: a cost-effectiveness analysis in France. BMC Medical Imaging, 2020, 20, 25.	1.4	10
10	68Ga-PSMA-11 PET/CT in restaging castration-resistant nonmetastatic prostate cancer: detection rate, impact on patients' disease management and adequacy of impact. Scientific Reports, 2020, 10, 2104.	1.6	33
11	Incidental Metastatic Melanoma Identified on 18F-FDOPA PET/CT With Confirmation by Histology. Clinical Nuclear Medicine, 2020, 45, 817-818.	0.7	6
12	Rare Extramedullary Cardiac Involvement of Recurrent Multiple Myeloma Suspected on 18F-FDG and Confirmed on 18F-Fluorocholine. Clinical Nuclear Medicine, 2020, 45, 916-918.	0.7	0
13	[68Ga]RGD Versus [18F]FDG PET Imaging in Monitoring Treatment Response of a Mouse Model of Human Glioblastoma Tumor with Bevacizumab and/or Temozolomide. Molecular Imaging and Biology, 2019, 21, 297-305.	1.3	10
14	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822.	0.6	22
15	Preclinical Evaluation of 68Ga-DOTA-NT-20.3: A Promising PET Imaging Probe To Discriminate Human Pancreatic Ductal Adenocarcinoma from Pancreatitis. Molecular Pharmaceutics, 2019, 16, 2776-2784.	2.3	18
16	18F-Fluorocholine PET/CT Imaging of Brown Tumors in a Patient With Severe Primary Hyperparathyroidism. Clinical Nuclear Medicine, 2019, 44, 971-974.	0.7	10
17	Impact of sodium 18F-fluoride PET/CT, 18F-fluorocholine PET/CT and whole-body diffusion-weighted MRI on the management of patients with prostate cancer suspicious for metastasis: a prospective multicentre study. World Journal of Urology, 2019, 37, 1587-1595.	1.2	10
18	Vertebral metastases from neuroendocrine tumours: How to avoid false positives on 68Ga-DOTA-TOC PET using CT pattern analysis?. European Radiology, 2018, 28, 3943-3952.	2.3	10

#	Article	IF	Citations
19	Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. Lancet Oncology, The, 2018, 19, e534-e545.	5.1	98
20	Editorial Comment: Advances in MRI and PET of the prostate: concurrence or complementarity?. European Radiology, 2018, 28, 3138-3140.	2.3	0
21	18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study. PLoS ONE, 2018, 13, e0191487.	1.1	18
22	Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma. Oncotarget, 2018, 9, 19307-19316.	0.8	12
23	Equivalent Dose Rate 1 Meter from Neuroendocrine Tumor Patients Exiting the Nuclear Medicine Department After Undergoing Imaging. Journal of Nuclear Medicine, 2017, 58, 1230-1235.	2.8	10
24	Reply. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 172-172.	3.3	0
25	A Method to Improve the Semiquantification of 18F-FDG Uptake: Reliability of the Estimated Lean Body Mass Using the Conventional, Low-Dose CT from PET/CT. Journal of Nuclear Medicine, 2016, 57, 753-758.	2.8	14
26	Tumor Heterogeneity Detected by 68Ga DOTATOC and 18F-FDG PET/CTs in One Malignant Insulinoma With Involvement of the Portal Splenic Confluence and Ovarian Metastases. Clinical Nuclear Medicine, 2016, 41, 874-876.	0.7	7
27	18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1995-2004.	3.3	67
28	68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models. Anticancer Research, 2016, 36, 4459-4466.	0.5	10
29	A Pilot Comparison of 18F-fluorocholine PET/CT, Ultrasonography and 123I/99mTc-sestaMIBI Dual-Phase Dual-Isotope Scintigraphy in the Preoperative Localization of Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism. Medicine (United States), 2015, 94, e1701.	0.4	145
30	Is 18F-Fluorocholine-Positron Emission Tomography/Computerized Tomography a New Imaging Tool for Detecting Hyperfunctioning Parathyroid Glands in Primary or Secondary Hyperparathyroidism?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4531-4536.	1.8	132
31	Whole-Body 18F-Fluorocholine (FCH) PET/CT and MRI of the Spine for Monitoring Patients With Castration-Resistant Prostate Cancer Metastatic to Bone. Clinical Nuclear Medicine, 2014, 39, 951-959.	0.7	10
32	Incidental uptake of ¹⁸ F-fluorocholine (FCH) in the head or in the neck of patients with prostate cancer. Radiology and Oncology, 2014, 48, 228-234.	0.6	44
33	Use of choline PET for studying hepatocellular carcinoma. Clinical and Translational Imaging, 2014, 2, 103-113.	1.1	17
34	Strengths and limitations of using 18 fluorine-fluorodihydroxyphenylalanine PET/CT for congenital hyperinsulinism. Expert Review of Endocrinology and Metabolism, 2014, 9, 477-485.	1.2	1
35	Consequence of the introduction of routine FCH PET/CT imaging for patients with prostate cancer: a dual centre survey. Radiology and Oncology, 2014, 48, 20-28.	0.6	8
36	18F-Fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 943-966.	3.3	101

#	Article	IF	Citations
37	A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection. Nuclear Medicine Communications, 2012, 33, 757-765.	0.5	22
38	Added value of early 18F-FDOPA PET/CT acquisition time in medullary thyroid cancer. Nuclear Medicine Communications, 2012, 33, 775-779.	0.5	41
39	Novel DOTA-Neurotensin Analogues for 111 In Scintigraphy and 68Ga PET Imaging of Neurotensin Receptor-Positive Tumors. Bioconjugate Chemistry, 2011, 22, 1374-1385.	1.8	48
40	Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nuclear Medicine Communications, 2010, 31, 389-397.	0.5	45
41	Detection of Hepatocellular Carcinoma with PET/CT: A Prospective Comparison of sup > 18 < sup > F. Fluorocholine and sup > 18 < sup > F. FDG in Patients with Cirrhosis or Chronic Liver Disease. Journal of Nuclear Medicine, 2010, 51, 1699-1706.	2.8	183
42	Application diagnostique de la tomographie par émission de positons en France. De la gamma-caméra modifiée à la machine hybride TEP/TDM Bulletin De L'Academie Nationale De Medecine, 2010, 194, 1559-1579.	0.0	0
43	Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1295-1301.	1.8	65
44	Early evaluation of the effects of chemotherapy with longitudinal FDG small-animal PET in human testicular cancer xenografts: early flare response does not reflect refractory disease. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 396-405.	3.3	20
45	Current evaluation of the clinical utility of Fluoromethylcholine-(18F) PET/CT in Prostate Cancer. Brazilian Archives of Biology and Technology, 2008, 51, 71-75.	0.5	1
46	Improvement of semi-quantitative small-animal PET data with recovery coefficients: A phantom and rat study. Nuclear Medicine Communications, 2007, 28, 813-822.	0.5	9
47	FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Brazilian Archives of Biology and Technology, 2007, 50, 77-90.	0.5	10
48	PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1285-1289.	3.3	128
49	18F-Choline PET/CT for Initial Staging of Advanced Prostate Cancer. American Journal of Roentgenology, 2006, 187, W618-W621.	1.0	18
50	Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?. Journal of Nuclear Medicine, 2006, 47, 1455-62.	2.8	90
51	Impact of CT and 18F-deoxyglucose positron emission tomography image fusion for conformal radiotherapy in esophageal carcinoma. International Journal of Radiation Oncology Biology Physics, 2005, 63, 340-345.	0.4	128
52	Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non–small-cell lung cancer. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1432-1441.	0.4	117
53	Usefulness of combination of high-resolution ultrasonography and dual-phase dual-isotope iodine 123/technetium Tc 99m sestamibi scintigraphy for the preoperative localization of hyperplastic parathyroid glands in renal hyperparathyroidism. American Journal of Kidney Diseases, 2005, 45, 344-352.	2.1	60
54	Detection of recurrent colorectal carcinoma by 18F-FDG: comparison of the clinical performances of FDG PET and FDG CDET. Nuclear Medicine Communications, 2004, 25, 105-113.	0.5	5

#	Article	IF	CITATIONS
55	Diffusely Increased F-18 FDG Uptake in Bone Marrow in a Patient With Acute Anemia and Recent Erythropoietin Therapy. Clinical Nuclear Medicine, 2003, 28, 771-772.	0.7	30
56	Fluorodeoxyglucose Imaging Using a Coincidence Gamma Camera to Detect Head and Neck Squamous Cell Carcinoma and Response to Chemotherapy. Annals of Otology, Rhinology and Laryngology, 2002, 111, 763-771.	0.6	12
57	CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. International Journal of Radiation Oncology Biology Physics, 2001, 49, 1249-1257.	0.4	127
58	Use of a Coincidence Gamma Camera to Detect Primary Tumor with 18Fluoro-2-Deoxy-Glucose in Cervical Lymph Node Metastases from an Unknown Origin. Annals of Otology, Rhinology and Laryngology, 2000, 109, 755-760.	0.6	7